No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

USA: In a significant advancement for the treatment of severe alopecia areata (AA), long-term data from two phase III ...

Disappointingly, a third drug also tested in the study failed to show additive efficacy in RA when combined with tofacitinib ...

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from ...

Survey results revealed that 66% of pediatric rheumatology providers reported prescribing off-label Janus kinase inhibitors to treat juvenile dermatomyositis. Janus kinase (JAK) inhibitors are ...

JAK inhibitors, such as ruxolitinib cream and abrocitinib, present promising alternatives to existing therapies for managing moderate to severe atopic dermatitis, offering effective treatment options.